Project Grant K01CA304486
Award Date 8/6/25
Completion Date 7/31/30
Dollars Obligated $195K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This federal Project Grant award of $352,000.00, funded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the Sloan-Kettering Institute for Cancer Research to augment the in vivo efficacy of a novel lanosterol synthase inhibitor in glioblastoma. The research project aims to investigate innovative approaches to enhance the therapeutic potential of this novel compound for treating glioblastoma, an aggressive...
- This $3,155,815 Project Grant award from the National Cancer Institute (NCI), under the CFDA 93.394 Cancer Detection and Diagnosis Research program, supports research to develop advanced magnetic resonance imaging techniques for non-invasive measurement of glutamate metabolism in glioblastoma brain tumors. The primary awardee is Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, which will leverage its expertise in medical research, imaging technologies, and...
- This Project Grant award of $687,279 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to uncover the effects of standard-of-care therapy on immune and neoplastic cell population dynamics in pre-clinical mouse models of glioblastoma (GBM) and analysis of human GBM samples. The goal is to identify tumor microenvironment areas of therapeutic...
- This federal Project Grant award of $109,076.00, awarded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) on December 17, 2025, supports research to immuno-modulate diffuse midline glioma, an aggressive pediatric brain tumor, through epigenetic reprogramming. The project, led by the University of Miami, aims to advance scientific understanding and develop new treatment approaches for this deadly disease. The 4-year project period runs through September 1, 2029. The...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $147,083 to the Icahn School of Medicine at Mount Sinai to conduct research on "Deconstructing Pathogenic Myelopoiesis in Cancer Immunosuppression and Treatment Resistance". The key objectives are to study the epigenetic regulation and priming of regulatory pathways in tumor-educated bone marrow myeloid progenitors, with a focus on understanding how the NRF2 oxidative...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $2,820,337.00 to the Regents of the University of Michigan to develop new methods to directly measure metabolic pathway activity in mouse models and patients with glioblastomas (GBMs), which are deadly and incurable brain cancers. The goal is to identify optimal metabolic treatment strategies for GBM patients by evaluating the safety, on-target activity, and potential efficacy of new...
- This $638,697 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research by the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University (CCLCM) to investigate the role of the SMARCA5 protein in the development and progression of glioblastoma, an aggressive type of brain cancer. The goal of the research is...
- This federal Project Grant award for $2,679,816.00, provided by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), supports four integrated research projects that aim to address key aspects of mutant p53 and its role in tumor metastasis. The funded research, led by principal investigator James Manfredi, focuses on systematic studies of mutant p53 allelic variation, mechanisms of the hot-spot mutant p53R175H in tumor metastasis, defining the roles of mutant p53...
- This $2,691,173.00 Project Grant was awarded on September 24, 2025 by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) to the Icahn School of Medicine at Mount Sinai. The grant will support research to determine the mechanisms and impact of the bone-induced factor NRG3 in breast cancer bone metastasis progression, without the occurrence of initial cancer cell dissemination. The research aims to functionally characterize the NRG3 regulome, identify NRG3...
- The federal Project Grant award of $924,001.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research by the Sloan-Kettering Institute for Cancer Research to investigate the cellular and molecular origins of non-small cell lung cancer (NSCLC) brain metastasis. The research aims to enhance understanding of the mechanisms driving NSCLC brain metastasis, with the goal of developing innovative therapeutic...